Examining Elafibranor as a Treatment Option for PBC

Author(s):

Ryan Haumschild, PharmD, MS, MBA, CPEL ,Sandy Sallam, PharmD, BCACP, CDCES

Panelists discuss how elafibranor demonstrated significant efficacy in the ELATIVE trial, which strengthens confidence in its role as a long-term treatment option for patients with primary biliary cholangitis (PBC) who inadequately respond to ursodeoxycholic acid.

EP: 1.Presentation and Diagnosis of Primary Biliary Cholangitis

EP: 2.Available Treatment Options for PBC

EP: 3.Treatment Goals for Patients With PBC

EP: 4.Exploring Second-Line Treatments for PBC

Now Viewing

EP: 5.Examining Elafibranor as a Treatment Option for PBC

Video content above is prompted by the following:

Elafibranor received accelerated approval based on findings from the ELATIVE study. What are the key efficacy insights from this trial?
Elafibranor was also demonstrated to have long-term safety and efficacy at 3 years. How does this durability affect your clinical decision-making?